| 2026-07-30 | Press release | PDF Version · Q2 2026 |
| 2026-07-30 | Press release | Agios Reports Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-07-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-30 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-21 | Press release | Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease |
| 2026-07-07 | Press release | U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease |
| 2026-06-29 | Press release | Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET |
| 2026-06-18 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-13 | Press release | Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapiv |
| 2026-06-13 | Deck | EHA 2026 Investor Webcast Presentation_FINAL |
| 2026-06-10 | Press release | Agios Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-06-08 | Press release | Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 |
| 2026-06-01 | Press release | Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor |
| 2026-05-29 | Press release | Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes |
| 2026-05-22 | Press release | Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia |
| 2026-05-12 | Press release | Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease |
| 2026-05-12 | Press release | Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare H |
| 2026-04-29 | Press release | Agios Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-04-29 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-29 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-24 | Proxy | Definitive proxy statement |
| 2026-04-06 | Press release | PDF Version · Q1 2026 |
| 2026-03-31 | Press release | PDF Version |
| 2026-03-31 | Press release | Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting wi |
| 2026-03-02 | Press release | PDF Version |
| 2026-03-02 | Press release | Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates |
| 2026-02-13 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-12 | Press release | Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update |
| 2026-02-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-12 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-01-26 | Press release | PDF Version · Q4 2025 |
| 2026-01-14 | Deck | 44th Annual J.P. Morgan Healthcare Conference Presentation |
| 2026-01-12 | Press release | PDF Version |
| 2026-01-12 | Press release | Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth |
| 2026-01-12 | 8-K | Form 8-K, Item 7.01 |
| 2026-01-05 | Press release | PDF Version |
| 2026-01-05 | Press release | Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on |
| 2025-12-23 | Press release | PDF Version |
| 2025-12-23 | Press release | U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia |
| 2025-12-08 | Press release | PDF Version |